| Did death certificates and a death review process agree on lung cancer cause of death in the National Lung Screening Trial? |
27006427
|
Marcus PM, Doria-Rose VP, Gareen IF, Brewer B, Clingan K, Keating K, Rosenbaum J, Rozjabek HM, Rathmell J, Sicks J, Miller AB |
Clin Trials |
2016 |
NLST |
| CANARY Risk Management of Adenocarcinoma: The Future of Imaging? |
|
Finbar Foley
, Srinivasan Rajagopalan
, Sushravya M. Raghunath
, Jennifer M. Boland
, Ronald A. Karwoski
, Fabien Maldonado
, Brian J. Bartholmai
, Tobias Peikert
, |
j.semtcsv |
2016 |
NLST |
| Normative reference values of thoracic aortic diameter in American College of Radiology Imaging Network (ACRIN 6654) arm of National Lung Screening Trial. |
27203287
|
McComb BL, Munden RF, Duan F, Jain AA, Tuite C, Chiles C |
Clin Imaging |
2016 |
NLST |
| Development and Validation of Risk Models to Select Ever-Smokers for CT Lung Cancer Screening. |
27179989
|
Katki HA, Kovalchik SA, Berg CD, Cheung LC, Chaturvedi AK |
JAMA |
2016 |
NLST |
| The Potential Clinical, Resource Use, And Fiscal Impacts of Lung-Rads To Inform Lung Cancer Screening In Medicare |
|
J. Roth, S.D. Sullivan, S. Ramsey, B. Goulart |
Val Health |
2016 |
NLST |
| Lung Cancer Deaths in the National Lung Screening Trial Attributed to Nonsolid Nodules. |
27378239
|
Yip R, Yankelevitz DF, Hu M, Li K, Xu DM, Jirapatnakul A, Henschke CI |
Radiology |
2016 |
NLST |
| Factors Associated with a Positive Baseline Screening Exam Result in the National Lung Screening Trial. |
27387658
|
Balekian AA, Tanner NT, Fisher JM, Silvestri GA, Gould MK |
Ann Am Thorac Soc |
2016 |
NLST |
| Implementing low-dose computed tomography screening for lung cancer in Canada: implications of alternative at-risk populations, screening frequency, and duration. |
27330355
|
Evans WK, Flanagan WM, Miller AB, Goffin JR, Memon S, Fitzgerald N, Wolfson MC |
Curr Oncol |
2016 |
NLST |
| Prediction of lung cancer incidence on the low-dose computed tomography arm of the National Lung Screening Trial: A dynamic Bayesian network. |
27664507
|
Petousis P, Han SX, Aberle D, Bui AA |
Artif Intell Med |
2016 |
NLST |
| Estimation of the tumor size at cure threshold among aggressive non-small cell lung cancers (NSCLCs): evidence from the surveillance, epidemiology, and end results (SEER) program and the national lung screening trial (NLST). |
27925181
|
Goldwasser DL |
Int. J. Cancer |
2016 |
NLST |
| The Vancouver Lung Cancer Risk Prediction Model: Assessment by Using a Subset of the National Lung Screening Trial Cohort. |
27740906
|
White CS, Dharaiya E, Campbell E, Boroczky L |
Radiology |
2016 |
NLST |
| Evaluating Long-Term Outcomes via Computed Tomography in Lung Cancer Screening |
|
Dongfeng Wu, Ruiqi Liu, Beth Levitt, Tom Riley, Kathy B. Baumgartner |
J Biom Biostat |
2016 |
NLST |
| Prognostic Significance of a Negative Prostate Biopsy: An Analysis of Subjects Enrolled in a Prostate Cancer Screening Trial. |
27836710
|
Lewicki P, Shoag J, Golombos DM, Oromendia C, Ballman KV, Halpern JA, Stone BV, O'Malley P, Barbieri CE, Scherr DS |
J. Urol. |
2016 |
PLCO |
| Detection of High Grade Prostate Cancer among PLCO Participants Using a Prespecified 4-Kallikrein Marker Panel. |
27810449
|
Kim EH, Andriole GL, Crawford ED, Sjoberg DD, Assel M, Vickers AJ, Lilja H |
J. Urol. |
2016 |
PLCO |
| Reevaluating PSA Testing Rates in the PLCO Trial. |
27144870
|
Shoag JE, Mittal S, Hu JC |
N. Engl. J. Med. |
2016 |
PLCO |
| Prediagnostic aspirin use and mortality in women with stage I to III breast cancer: A cohort study in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial. |
27149646
|
Bradley MC, Black A, Freedman AN, Barron TI |
Cancer |
2016 |
PLCO |
| Lethal Prostate Cancer in the PLCO Cancer Screening Trial. |
27166670
|
Shoag J, Mittal S, Halpern JA, Scherr D, Hu JC, Barbieri CE |
Eur. Urol. |
2016 |
PLCO |
| Active follow-up versus passive linkage with cancer registries for case ascertainment in a cohort. |
27687075
|
Pinsky PF, Yu K, Black A, Huang WY, Prorok PC |
Cancer Epidemiol |
2016 |
PLCO |
| The Prostate, Lung, Colorectal and Ovarian Cancer (PLCO) Screening Trial Pathology Tissue Resource. |
27635065
|
Zhu CS, Huang WY, Pinsky PF, Berg CD, Sherman M, Yu KJ, Carrick DM, Black A, Hoover R, Lenz P, Williams C, Hawkins L, Chaloux M, Yurgalevitch S, Mathew S, Miller A, Olivo V, Khan A, Pretzel SM, Multerer D, Beckmann P, Broski KG, Freedman ND |
Cancer Epidemiol. Biomarkers Prev. |
2016 |
PLCO |
| Extended mortality results for ovarian cancer screening in the PLCO trial with median 15years follow-up. |
27615399
|
Pinsky PF, Yu K, Kramer BS, Black A, Buys SS, Partridge E, Gohagan J, Berg CD, Prorok PC |
Gynecol. Oncol. |
2016 |
PLCO |
